A5021568045- Diabetes Management and Research
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Treatment and Management
- Adolescent and Pediatric Healthcare
- Diet and metabolism studies
- Digestive system and related health
- Obesity, Physical Activity, Diet
- Celiac Disease Research and Management
- Childhood Cancer Survivors' Quality of Life
- Retinal Diseases and Treatments
- Metabolism, Diabetes, and Cancer
- Health and Medical Studies
- Birth, Development, and Health
- Lipoproteins and Cardiovascular Health
- Gestational Diabetes Research and Management
- Retinopathy of Prematurity Studies
- Thyroid Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Breastfeeding Practices and Influences
- Family Support in Illness
- Infant Nutrition and Health
- Mobile Health and mHealth Applications
- Diet, Metabolism, and Disease
Kinderkrankenhaus auf der Bult
2016-2025
Universidade Nova de Lisboa
2025
Medizinische Hochschule Hannover
2006-2024
Children's Hospital
2011-2024
Center for Children
2013-2024
Breakthrough
2024
Hannoversche Kinderheilanstalt
2007-2019
Boston Children's Hospital
2014
University of Helsinki
2013
Sapienza University of Rome
2012
Recent studies have shown that an artificial-pancreas system can improve glucose control and reduce nocturnal hypoglycemia. However, it is not known whether such results be replicated in settings outside the hospital.In this multicenter, multinational, randomized, crossover trial, we assessed short-term safety efficacy of artificial pancreas for levels patients (10 to 18 years age) with type 1 diabetes at a camp. In two consecutive overnight sessions, randomly assigned 56 receive treatment...
Insulin pump therapy may improve metabolic control in young patients with type 1 diabetes, but the association short-term diabetes complications is unclear.To determine whether rates of severe hypoglycemia and diabetic ketoacidosis are lower insulin compared injection children, adolescents, adults diabetes.Population-based cohort study conducted between January 2011 December 2015 446 centers participating Diabetes Prospective Follow-up Initiative Germany, Austria, Luxembourg. Patients...
The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function patients with recent-onset diabetes.We studied 334 patients, 10 to 20 years age, diabetes, fasting C-peptide levels more than 0.3 ng per milliliter (0.1 nmol liter), and detectable serum autoantibodies. Within 3 months after diagnosis, were randomly assigned receive one three study treatments: four doses...
Abstract The significant and growing global prevalence of diabetes continues to challenge people with (PwD), healthcare providers, payers. While maintaining near-normal glucose levels has been shown prevent or delay the progression long-term complications diabetes, a proportion PwD are not attaining their glycemic goals. During past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials real-world studies that use AID...
OBJECTIVE—To investigate thyroid autoimmunity in a very large nationwide cohort of children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS—Data were analyzed from 17,749 patients diabetes aged 0.1–20 years who treated 118 pediatric centers Germany Austria. Antibodies to thyroglobulin (anti-TG) thyroperoxidase (anti-TPO) measured documented at least once 7,097 patients. A total 49.5% these boys, the mean age was 12.4 (range 0.3–20.0 years), duration 4.5 0.0–19.5 years)....
OBJECTIVE—The aim of this data analysis was to ascertain the type and prevalence rate as well age sex distribution cardiovascular risk factors in 1 diabetic patients up 26 years age. RESEARCH DESIGN AND METHODS—Cardiovascular such obesity, hypertension, dyslipidemia, poor glycemic control, smoking were analyzed 27,358 who divided into three groups (prepubertal, pubertal, adult) using specifically designed diabetes software for prospective disease documentation. RESULTS—More than half per...
OBJECTIVE—To investigate the growth of children from pregnancies with gestational diabetes mellitus (GDM) and its association antenatal maternal, fetal, recent anthropometric parameters mother father. RESEARCH DESIGN AND METHODS—In 324 Caucasian women GDM, BMI before pregnancy, maternal glycemic values, measurements fetal abdominal circumference were recorded. The weight height infants measured at birth follow-up 5.4 years (range 2.5–8.5). In addition, somatic data routine examinations 6,...
We evaluated the effect of MD-Logic system on overnight glycemic control at patients' homes.Twenty-four patients (aged 12-43 years; average A1c 7.5 ± 0.8%, 58.1 8.4 mmol/mol) were randomly assigned to participate in two crossover periods, each including 6 weeks consecutive nights: one under closed loop and second sensor-augmented pump (SAP) therapy homes real-life conditions. The primary end point was time spent with sensor glucose levels below 70 mg/dL (3.9 mmol/L) overnight.Closed-loop...
<h3>Importance</h3> The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure complex dietary proteins may increase risk β-cell autoimmunity in children at genetic for diabetes. Extensively hydrolyzed formulas do not contain intact proteins. <h3>Objective</h3> To test hypothesis that weaning an extensively formula decreases cumulative incidence diabetes-associated autoantibodies young children. <h3>Design, Setting, and...
Severe hypoglycemic episodes are a barrier for achieving optimal glycemic control. Sensor-augmented pump (SAP) therapy with insulin in combination novel mechanism of automatic shutoff (low glucose suspend [LGS]) can be used to prevent and reduce hypoglycemia. In prospective study, we investigated the effect LGS algorithm on frequency hypoglycemia children adolescents type 1 diabetes under real-life conditions.Twenty-one patients (10.8±3.8 years old, duration 5.9±3.0 years, 3.7±1.7 glycated...
A sensor-augmented insulin pump (SAP) using the MiniMed® 640G system with SmartGuard™ technology allows an automatic stop of delivery based on prediction low glucose levels. Since pediatric patients are particularly prone to hypoglycemia, this device may offer additional protection beyond conventional therapy.This prospective, multicenter user evaluation assessed 6 weeks SAP SmartGuard (threshold setting for hypoglycemia: 70 mg/dL) compared a preceding period 2 only. The primary outcome was...
Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact extensively hydrolyzed formulas.To test hypothesis that weaning an formula decreases cumulative incidence young children.An international double-blind randomized clinical trial 2159 infants human leukocyte antigen-conferred susceptibility and a first-degree relative recruited from May 2002 January 2007 78 study centers 15 countries; 1081...
To describe the diabetes phenotype in Wolfram syndrome compared with type 1 diabetes, to investigate effect of glycemic control on neurodegenerative process, and assess genotype-phenotype correlation.The clinical data 50 patients syndrome-related (WSD) were reviewed 24,164 diabetes. Patients a mean HbA1c during childhood adolescence ≤7.5 >7.5% respect occurrence additional symptoms. The wolframin (WFS1) gene was screened for mutations 39 patients. WFS1 genotypes examined correlation age at...
Artificial pancreas (AP) systems have shown an improvement in glucose control and a reduced risk of nocturnal hypoglycemia under controlled conditions but remain to be evaluated daily-life conditions.To assess the feasibility, safety, efficacy MD-Logic AP controlling levels patient's home.Two-arm study, each covering four consecutive nights comparing ('closed-loop' arm) with sensor-augmented pump therapy ('control' arm). Fifteen patients (mean age 19 ± 10.4 yr, A1c 7.5 0.5% or 58 5.9...
To investigate the safety, tolerability, and pharmacokinetics of liraglutide in adolescents with obesity.This was a randomized, double-blind, placebo-controlled trial. Twenty-one subjects, aged 12-17 years Tanner stage 2-5, obesity (body mass index [BMI] corresponding to both BMI ≥95th percentile for age sex ≥30 kg/m2 adults; additionally, ≤45 kg/m2) were randomized (2:1) receive 5 weeks treatment (0.6 mg weekly dose increase maximum 3.0 last week) (n = 14) or placebo 7). The primary...